Time: 2023-07-15
Views: 402
According to News Medical Lifesciences, the Food and Drug Administration (FDA) has granted a grant of US $3.9 million to the Tobacco Research Center of Ohio State University Comprehensive Cancer Center to assess the impact of Electronic cigarette taste on smoking behavior of current adult smokers.
The study will be co led by Theodore Wagner, director of the Ohio State University Tobacco Research Center, and Tracy Smith of the Hollins Cancer Center at South Carolina Medical University.
Wagner said, "The FDA must decide how to balance the goals of protecting young people and providing harm reduction options for adults. This new experiment will produce key data to help make more informed public health decisions with lasting impact
Wagner stated: "FDA is currently making regulatory decisions on the taste of Electronic cigarette based on incomplete scientific data. Existing data shows that smokers also prefer Electronic cigarette with taste. Although some research shows that Electronic cigarette with taste may be more conducive to switching to smoking, the seriousness of these studies is not enough for FDA to make regulatory decisions based on them. Our research will provide FDA with information for the first time on whether the taste of Electronic cigarette is good for adult smokers No useful clear information
This nationwide Randomized controlled trial will recruit up to 1500 smokers nationwide. The researchers will measure the impact of Electronic cigarette taste on product acceptance and attractiveness, desire for cigarettes, symptoms, dependence and smoking behavior. The combined nicotine replacement therapy will be used as the comparison group to determine the potential gain of Electronic cigarette compared with nicotine replacement therapy.
Wagner said: "If our research proves that the Electronic cigarette with taste has not significantly improved in terms of switching to smoking, it may not be justifiable to continue to sell these products; however, if the improvement is significant, these research results will provide key comparisons for the current FDA regulatory provisions and contribute to future decisions."